INTRODUCTION to aVNS

For a broader introduction to auricular vagus nerve stimulation (aVNS), please explore our aVNS Clinical Evidence Guide. It provides important background on how aVNS works, together with a detailed review of the clinical research and its potential applications across a wide range of health conditions.

Cardiovascular Health

The heart does not work in isolation. Its rate and rhythm are continually adjusted by the autonomic nervous system in response to activity, posture, breathing, sleep, stress and the changing needs of the body. 

The vagus nerve plays an important part in this regulation. It helps slow and stabilize heart rate when appropriate and contributes to the balance between sympathetic stimulation—which prepares the cardiovascular system for activity—and parasympathetic activity, which supports rest, recovery and cardiovascular stability. 

This means that supporting healthier vagal regulation could potentially influence several aspects of cardiovascular health at the same time. 

Clinical research with aVNS has reported encouraging effects involving:  

• heart-rate and rhythm regulation 

• healthier autonomic balance 

• blood-pressure regulation 

• reduced excessive sympathetic activity 

• substantial reductions in atrial fibrillation burden 

• inflammatory processes associated with cardiovascular disease 

• and the cardiovascular response to physical or physiological stress 

HRV provides one objective way of observing some of these autonomic effects and is discussed in the Autonomic Regulation section. However, the potential cardiovascular effects of aVNS extend well beyond HRV. 

Supporting cardiovascular regulation 

One of the potential advantages of aVNS is that it does not target only a single cardiovascular measurement. 

The autonomic nervous system simultaneously influences heart rate, cardiac electrical activity, blood-vessel tone and blood pressure. It also interacts with inflammatory and metabolic processes that can affect cardiovascular health over time. 

Research has demonstrated that stimulating the vagus nerve can shift this regulation—reducing excessive sympathetic activity and strengthening parasympathetic or vagal influence in appropriate settings. 

For someone whose cardiovascular symptoms occur alongside stress, poor sleep or autonomic dysfunction, supporting this underlying regulatory system may therefore be particularly relevant. 

The goal is not simply to make the heart beat more slowly. It is to help the cardiovascular system become more stable, adaptable and appropriately responsive to changing demands. 

Blood-pressure regulation 

Blood pressure changes constantly throughout the day. The autonomic nervous system helps make rapid adjustments when we stand, exercise, experience stress or sleep. 

Clinical research suggests that aVNS can influence this regulation, with studies reporting improvements in blood pressure in some populations. This may be particularly relevant when elevated or unstable blood pressure occurs alongside excessive sympathetic activity, chronic stress or impaired autonomic regulation. 

The potential benefit is therefore not simply “lowering blood pressure.” It is supporting the body’s ability to regulate blood pressure more appropriately as circumstances change. 

Blood pressure, however, depends on much more than autonomic activity. The health and flexibility of the blood vessels, kidney function, hormones, metabolic health, body weight, medications and other factors can all contribute. For someone in whom vascular or other factors are dominant, improving vagal regulation alone may produce a smaller change. 

Atrial fibrillation: an important clinical finding 

AF is an abnormal heart rhythm in which the upper chambers of the heart beat irregularly. In paroxysmal AF, episodes come and go, and fluctuations in autonomic activity can contribute to triggering or maintaining episodes in susceptible people. 

Some of the most compelling cardiovascular evidence for aVNS comes from research involving paroxysmal atrial fibrillation (AF). 

What has the research found?

In a randomized clinical study, people with paroxysmal AF used low-level electrical stimulation through the ear for one hour each day over six months. Heart rhythm was objectively assessed using approximately two weeks of continuous ECG monitoring at baseline and again at three and six months, allowing researchers to measure AF burden—the proportion of monitored time actually spent in atrial fibrillation.

The results were striking. 

At six months, AF burden was 85% lower in those receiving active stimulation than in the comparison group, after taking their starting AF burden into account.

Almost half of those receiving active stimulation achieved a greater than 75% reduction in their AF burden, compared with only 5% of those in the comparison group.

These findings are particularly meaningful because the improvement was objectively recorded by ECG. Researchers were not simply asking people whether they experienced fewer palpitations—they could demonstrate that their hearts were actually spending substantially less time in atrial fibrillation.

WHY MIGHT AVNS AFFECT AN ABNORMAL HEART RHYTHM? 

Atrial fibrillation is not purely an electrical problem. The environment surrounding the heart’s electrical system also matters. 

Autonomic imbalance, excessive sympathetic activation and inflammation can all influence the likelihood that AF develops or persists. 

Vagus nerve stimulation may be particularly valuable because it may influence several of these factors at the same time.

In the AF study, the reduction in abnormal heart rhythm was accompanied by changes in autonomic regulation and inflammation, including an approximately 23% reduction in the inflammatory marker TNF-α compared with the comparison group.

There is another interesting aspect of the findings. Participants used stimulation for only one hour each day, yet the reduction in AF was detected during prolonged ECG monitoring—not simply while the stimulation was taking place.

Together, these findings suggest that repeated aVNS may help create a more stable physiological environment which may lower the frequency and duration of atrial fibrillation.

What does this mean for someone with AF?

For someone with recurrent paroxysmal AF, this has important implications. Fewer episodes and substantially less time spent in AF could mean fewer palpitations, less disruption of sleep, exercise and everyday activities, and a lower overall burden from the condition.

Importantly, reducing the amount of time spent in AF may also have implications beyond symptom relief. Greater AF burden has been associated with a higher risk of important complications, including blood-clot formation, stroke or other thromboembolic events, heart failure and progression toward more persistent forms of AF. Therefore, if a treatment genuinely reduces both the frequency and duration of AF episodes, it could potentially contribute to reducing some of the longer-term risks associated with the condition, although the extent to which reducing AF burden translates into lower complication rates will depend on the individual and remains an area of ongoing research.

For a condition as clinically important as AF, the combination of substantially reduced AF burden, objectively recorded changes in heart rhythm, and accompanying changes in autonomic and inflammatory regulation makes this an especially promising treatment approach in combination with established AF measures.

The wider cardiovascular picture 

The cardiovascular research becomes particularly encouraging when considered alongside findings from other areas of aVNS research. 

Studies have demonstrated effects on sympathetic and parasympathetic activity, heart-rate regulation, blood-pressure responses and inflammatory signalling. Research in POTS has shown that aVNS can improve the excessive cardiovascular response to standing, while AF studies demonstrate that vagal stimulation can influence an objectively recorded cardiac rhythm disorder. 

Together, these findings suggest that the cardiovascular potential of aVNS is broader than simply “improving HRV.” 

The emerging picture is that aVNS may help support the regulatory systems that keep heart rate, rhythm, blood pressure and circulation appropriately controlled—and help the cardiovascular system respond more effectively to stress, activity and changing physiological demands. 

For people in whom autonomic imbalance, excessive sympathetic activity or inflammation contributes to cardiovascular symptoms, this provides a promising basis for exploring aVNS as an additional way of supporting cardiovascular regulation. 

Explore Luminnova InnateSignal™

Learn more about the Luminnova InnateSignal™ aVNS Program, including how the program works, what to expect, treatment options and how to determine whether InnateSignal™ may be appropriate for you.

Click here to explore the InnateSignal™ aVNS Program.